Search

Objective: This study was conducted among the dental students to evaluate the knowledge and attitude towards pharmacovigilance and adverse drug reactions reporting among the dental students in a private university, Malaysia. Methods: The survey was carried out among the pre-final and final year dental students using a pre-validated questionnaire that included the demographics details and survey items related to knowledge and perception aspects towards adverse drug reactions and pharmacovigilance. The questionnaire was distributed to the participants (n=100). A total of 61 questionnaires were duly filled out, giving a response rate of 76.25%. The survey data was analyzed using SPSS version 20. Results: The overall mean score on knowledge among the dental students was found to be 15.84. The study also observed that mean score on attitude in pre-final year and final year dental students were 11.03 and 20.44 respectively. The overall mean score for attitude on ADRs reporting and pharmacovigilance was found to be 22.65. Conclusion: The results show that knowledge of dental students who participated in the study towards pharmacovigilance and adverse drug reaction reporting was low. However, 15.6% of pre-final year students and 27.6% of final year students expressed positive attitude towards pharmacovigilance and ADRs reporting. As part of future health care professionals, they are expected to have sound knowledge and positive attitude towards pharmacovigilance activities. Key words: Adverse Drug Reactions, Attitude, Dental Students, Knowledge, Pharmacovigilance.

Cayratia trifolia is used as diuretic, in tumors, neuralgia and splenopathy. However, compounds depicting anti-ovarian cancer activities from this plant source have not yet been identified and structurally characterized till date. In the present study, X-ray structure of epifriedelanol, a bioactive compound, isolated from the ethanolic extract of the C. trifolia and its binding affinities against a few proteins (HER2, EGFR and CXCR4) that are reported to get overexpressed under ovarian cancer had been thoroughly studied by using molecular docking means. Binding affinities of the compound vis-à-vis that of carboplatin, a FDA approved drug to the ovarian cancer, to interact with the protein targets are quite impressive. The drug-likeness properties of the epifriedelanol and scope to develop the compound as a potent anti-ovarian cancer drug are discussed in this paper.